| Unit 1 Fundamental Principles of Pharmacology |
|
|
1 Introduction to Pharmacology: Concepts and Connections |
|
|
2 | (11) |
|
Brief History of Pharmacology |
|
|
3 | (1) |
|
Pharmacology: The Study of Medicines |
|
|
4 | (1) |
|
Characteristics of an Ideal Drug |
|
|
5 | (1) |
|
|
|
6 | (1) |
|
|
|
6 | (1) |
|
|
|
7 | (2) |
|
Connecting Pharmacology to Clinical Nursing Practice |
|
|
9 | (4) |
|
|
|
13 | (13) |
|
|
|
14 | (1) |
|
Brief History of Drug Legislation |
|
|
15 | (2) |
|
|
|
17 | (1) |
|
The U.S. Food and Drug Administration |
|
|
17 | (1) |
|
|
|
18 | (2) |
|
Changes to the Drug Approval Process |
|
|
20 | (1) |
|
Prescription and Over-the-Counter Drugs |
|
|
21 | (1) |
|
|
|
22 | (1) |
|
Prescriptive Authority for Nurses |
|
|
22 | (4) |
|
|
|
26 | (19) |
|
Introduction to Pharmacokinetics |
|
|
27 | (1) |
|
Primary Processes of Pharmacokinetics |
|
|
28 | (17) |
|
|
|
29 | (4) |
|
Drug Concentration and Dose |
|
|
33 | (1) |
|
|
|
33 | (1) |
|
Blood Flow to the Absorption Site |
|
|
33 | (1) |
|
|
|
34 | (1) |
|
|
|
34 | (1) |
|
|
|
34 | (6) |
|
Time-Response Relationships |
|
|
40 | (5) |
|
|
|
45 | (10) |
|
|
|
46 | (1) |
|
|
|
47 | (1) |
|
Dose-Response Relationship |
|
|
48 | (1) |
|
|
|
48 | (2) |
|
|
|
50 | (1) |
|
|
|
51 | (1) |
|
|
|
51 | (4) |
|
5 Adverse Drug Effects and Drug Interactions |
|
|
55 | (15) |
|
|
|
56 | (6) |
|
|
|
62 | (8) |
|
6 Medication Errors and Risk Reduction |
|
|
70 | (14) |
|
Medication Errors and Their Impact on Healthcare |
|
|
71 | (2) |
|
Factors Contributing to Medication Errors |
|
|
73 | (1) |
|
Drug Names and Medication Errors |
|
|
74 | (1) |
|
Reporting Medication Errors |
|
|
75 | (1) |
|
Strategies for Reducing Medication Errors |
|
|
76 | (8) |
|
7 The Role of Complementary and Alternative Therapies in Pharmacotherapy |
|
|
84 | (14) |
|
Types of Complementary and Alternative Therapies |
|
|
85 | (1) |
|
History of Herbal Therapies |
|
|
86 | (1) |
|
Standardization of Herbal Products |
|
|
86 | (2) |
|
Dietary Supplement Regulation |
|
|
88 | (2) |
|
|
|
90 | (2) |
|
|
|
92 | (6) |
| Unit 2 Pharmacology and the Nurse-Patient Relationship |
|
|
8 Pharmacotherapy During Pregnancy and Lactation |
|
|
98 | (12) |
|
Rationale for Drug Use During Pregnancy and Lactation |
|
|
99 | (1) |
|
Pharmacotherapy During Pregnancy |
|
|
99 | (5) |
|
Pharmacotherapy During Lactation |
|
|
104 | (6) |
|
9 Pharmacotherapy of the Pediatric Patient |
|
|
110 | (13) |
|
Testing and Labeling of Pediatric Drugs |
|
|
111 | (2) |
|
Pharmacokinetic Variables in Pediatric Patients |
|
|
113 | (1) |
|
Pharmacologic Implications Associated with Growth and Development |
|
|
114 | (3) |
|
Medication Safety for Pediatric Patients |
|
|
117 | (1) |
|
Determining Pediatric Drug Dosages |
|
|
117 | (1) |
|
Adverse Drug Reactions in Children and Promoting Adherence |
|
|
118 | (5) |
|
10 Pharmacotherapy of the Geriatric Patient |
|
|
123 | (10) |
|
|
|
124 | (1) |
|
Physiologic Changes Related to Aging |
|
|
125 | (1) |
|
Pharmacokinetic and Pharmacodynamic Changes in Older Adults |
|
|
125 | (2) |
|
Adherence and Drug Misuse Among Older Adults |
|
|
127 | (1) |
|
Adverse Drug Reactions in Older Adults |
|
|
128 | (5) |
|
11 Individual Variations in Drug Responses |
|
|
133 | (9) |
|
|
|
134 | (1) |
|
Cultural and Ethnic Variables |
|
|
134 | (2) |
|
|
|
136 | (1) |
|
|
|
137 | (5) |
| Unit 3 Pharmacology of the Autonomic Nervous System |
|
|
12 Review of Neurotransmitters and the Autonomic Nervous System |
|
|
142 | (13) |
|
Overview of the Nervous System |
|
|
143 | (1) |
|
Structure and Function of the Autonomic Nervous System |
|
|
144 | (2) |
|
|
|
146 | (2) |
|
|
|
148 | (2) |
|
Cholinergic Receptors and Neurotransmitters |
|
|
149 | (1) |
|
Termination of Acetylcholine Action |
|
|
150 | (1) |
|
|
|
150 | (2) |
|
Alpha-Adrenergic Receptors |
|
|
151 | (1) |
|
Beta-Adrenergic Receptors |
|
|
151 | (1) |
|
Termination of Norepinephrine Action |
|
|
151 | (1) |
|
Regulation of Autonomic Functions |
|
|
152 | (1) |
|
Classifying Autonomic Drugs |
|
|
152 | (3) |
|
|
|
155 | (15) |
|
|
|
156 | (2) |
|
|
|
158 | (3) |
|
Prototype Drugs: Bethanechol (Urecholine) |
|
|
159 | (2) |
|
|
|
161 | (1) |
|
Pharmacotherapy of Myasthenia Gravis |
|
|
161 | (5) |
|
Prototype Drugs: Pyridostigmine (Mestinon, Regonol) |
|
|
163 | (1) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Cholinergic Agonists |
|
|
164 | (2) |
|
|
|
166 | (4) |
|
14 Cholinergic Antagonists |
|
|
170 | (15) |
|
Classification of Cholinergic Antagonists |
|
|
171 | (1) |
|
|
|
172 | (4) |
|
Prototype Drugs: Atropine (Atropen) |
|
|
174 | (2) |
|
Nicotinic Antagonists: Ganglionic Blockers |
|
|
176 | (1) |
|
Nicotinic Antagonists: Neuromuscular Blockers |
|
|
177 | (8) |
|
Prototype Drugs: Succinylcholine (Anectine, Quelicin) |
|
|
178 | (3) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Cholinergic (Muscarinic) Antagonists |
|
|
181 | (4) |
|
|
|
185 | (16) |
|
Actions of Adrenergic Agonists |
|
|
186 | (1) |
|
Mechanisms of Action of Adrenergic Agonists |
|
|
186 | (1) |
|
Classification of Adrenergic Agonists |
|
|
187 | (1) |
|
Nonselective Adrenergic Agonists |
|
|
188 | (4) |
|
Prototype Drug: Epinephrine (Adrenalin) |
|
|
190 | (2) |
|
Alpha-Adrenergic Agonists |
|
|
192 | (2) |
|
Prototype Drug: Phenylephrine (Neo-Synephrine) |
|
|
193 | (1) |
|
|
|
194 | (7) |
|
Prototype Drug: Isoproterenol (Isuprel) |
|
|
195 | (2) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Adrenergic Agonists |
|
|
197 | (4) |
|
16 Adrenergic Antagonists |
|
|
201 | (17) |
|
Actions of Adrenergic Antagonists |
|
|
202 | (1) |
|
Alpha-Adrenergic Antagonists |
|
|
202 | (4) |
|
Prototype Drug: Prazosin (Minipress) |
|
|
205 | (1) |
|
Beta-Adrenergic Antagonists |
|
|
206 | (12) |
|
Prototype Drug: Propranolol (Inderal, InnoPran XL) |
|
|
208 | (3) |
|
Prototype Drug: Metoprolol (Lopressor, Toprol XL) |
|
|
211 | (2) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Adrenergic Antagonists |
|
|
213 | (5) |
| Unit 4 Pharmacology of the Central Nervous System |
|
|
17 Review of the Central Nervous System |
|
|
218 | (9) |
|
Scope of Central Nervous System Pharmacology |
|
|
219 | (1) |
|
Neurons and Neurotransmission |
|
|
220 | (2) |
|
Structural Divisions of the Central Nervous System |
|
|
222 | (2) |
|
Functional Systems of the Central Nervous System |
|
|
224 | (3) |
|
18 Pharmacotherapy of Anxiety and Sleep Disorders |
|
|
227 | (26) |
|
|
|
228 | (3) |
|
|
|
231 | (3) |
|
Management of Anxiety and Sleep Disorders |
|
|
234 | (3) |
|
Pharmacotherapy of Anxiety and Insomnia |
|
|
237 | (16) |
|
Prototype Drug: Lorazepam (Ativan) |
|
|
238 | (3) |
|
Prototype Drug: Zolpidem (Ambien, Edluar, Others) |
|
|
241 | (5) |
|
Prototype Drug: Phenobarbital (Luminal) |
|
|
246 | (2) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Anxiety or Sleep Disorders |
|
|
248 | (5) |
|
19 Pharmacotherapy of Mood Disorders |
|
|
253 | (28) |
|
Categories of Mood Disorders |
|
|
254 | (1) |
|
Major Depressive Disorder |
|
|
254 | (1) |
|
Pathophysiology of Depression |
|
|
255 | (1) |
|
|
|
256 | (1) |
|
Nonpharmacologic Therapies for Depression |
|
|
257 | (1) |
|
Pharmacotherapy of Depression |
|
|
258 | (15) |
|
Selective Serotonin Reuptake Inhibitors |
|
|
259 | (4) |
|
Prototype Drug: Fluoxetine (Prozac) |
|
|
261 | (2) |
|
|
|
263 | (4) |
|
Prototype Drug: Venlafaxine (Effexor) |
|
|
264 | (3) |
|
Tricyclic Antidepressants |
|
|
267 | (2) |
|
Prototype Drug: Imipramine (Tofranil) |
|
|
268 | (1) |
|
Monoamine Oxidase Inhibitors |
|
|
269 | (17) |
|
Prototype Drug: Phenelzine (Nardil) |
|
|
270 | (2) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Antidepressants |
|
|
272 | (1) |
|
|
|
273 | (1) |
|
Drugs for Bipolar Disorder |
|
|
274 | (7) |
|
Prototype Drug: Lithium Carbonate (Eskalith, Lithobid) |
|
|
274 | (7) |
|
20 Pharmacotherapy of Psychoses |
|
|
281 | (23) |
|
Characteristics of Psychoses |
|
|
282 | (1) |
|
Symptoms of Schizophrenia |
|
|
283 | (1) |
|
Etiology of Schizophrenia |
|
|
284 | (1) |
|
|
|
284 | (2) |
|
|
|
286 | (18) |
|
First-Generation Antipsychotics |
|
|
288 | (5) |
|
Prototype Drug: Chlorpromazine |
|
|
290 | (1) |
|
Prototype Drug: Haloperidol (Haldol) |
|
|
291 | (2) |
|
Second-Generation (Atypical) Antipsychotics |
|
|
293 | (41) |
|
Prototype Drug: Risperidone (Risperdal) |
|
|
293 | (4) |
|
Prototype Drug: Aripiprazole (Abilify) |
|
|
297 | (2) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Antipsychotics |
|
|
299 | (5) |
|
21 Pharmacotherapy of Degenerative Diseases of the Central Nervous System |
|
|
304 | (26) |
|
Degenerative Diseases of the Central Nervous System |
|
|
305 | (1) |
|
|
|
306 | (1) |
|
Pharmacotherapy of Parkinson's Disease |
|
|
307 | (8) |
|
Prototype Drug: Levodopa and Carbidopa (Sinemet, Parcopa) |
|
|
308 | (3) |
|
Prototype Drug: Pramipexole (Mirapex) |
|
|
311 | (3) |
|
Prototype Drug: Benztropine (Cogentin) |
|
|
314 | (1) |
|
|
|
315 | (2) |
|
Pharmacotherapy of Alzheimer's Disease |
|
|
317 | (3) |
|
Prototype Drug: Donepezil (Aricept) |
|
|
319 | (1) |
|
|
|
320 | (5) |
|
Prototype Drug: Interferon Beta-lb (Betaseron, Extavia) |
|
|
322 | (3) |
|
Amyotrophic Lateral Sclerosis |
|
|
325 | (5) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Neurodegenerative Disorders |
|
|
325 | (5) |
|
22 Pharmacotherapy of Seizures |
|
|
330 | (28) |
|
Characteristics of Seizure Disorders |
|
|
331 | (3) |
|
Classification of Seizure Disorders |
|
|
334 | (5) |
|
|
|
334 | (1) |
|
|
|
335 | (4) |
|
|
|
339 | (19) |
|
Prototype Drug: Diazepam (Valium) |
|
|
342 | (2) |
|
Prototype Drug: Phenytoin (Dilantin, Phenytek) |
|
|
344 | (2) |
|
Prototype Drug: Carbamazepine (Carbatrol, Tegretol, Others) |
|
|
346 | (1) |
|
Prototype Drug: Ethosuximide (Zarontin) |
|
|
347 | (1) |
|
Prototype Drug: Gabapentin (Neurontin) |
|
|
348 | (1) |
|
Prototype Drug: Valproic Acid (Depacon, Depakene, Depakote) |
|
|
349 | (1) |
|
Other Miscellaneous Drugs |
|
|
350 | (98) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Seizures |
|
|
353 | (5) |
|
23 Pharmacotherapy of Muscle Spasms and Spasticity |
|
|
358 | (17) |
|
Etiology and Pathophysiology of Muscle Spasms and Spasticity |
|
|
359 | (1) |
|
Nonpharmacologic Therapies for Muscle Spasms and Spasticity |
|
|
360 | (1) |
|
Pharmacotherapy of Muscle Spasms |
|
|
361 | (5) |
|
Prototype Drug: Cyclobenzaprine (Amrix) |
|
|
363 | (3) |
|
Pharmacotherapy of Muscle Spasticity |
|
|
366 | (4) |
|
Prototype Drug: Dantrolene (Dantrium, Revonto) |
|
|
366 | (4) |
|
Skeletal Muscle Relaxants as Surgical Adjuncts |
|
|
370 | (5) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Muscle Spasms and Spasticity |
|
|
370 | (5) |
|
24 Central Nervous System Stimulants and Drugs for Attention-Deficit/Hyperactivity Disorder |
|
|
375 | (17) |
|
Characteristics of Central Nervous System Stimulants |
|
|
376 | (1) |
|
Etiology and Pathophysiology of Attention-Deficit/Hyperactivity Disorder |
|
|
377 | (1) |
|
Pharmacotherapy of Attention-Deficit/Hyperactivity Disorder |
|
|
378 | (6) |
|
Prototype Drug: Amphetamine and Dextroamphetamine (Adderall, Adderall XR) |
|
|
380 | (2) |
|
Prototype Drug: Atomoxetine (Strattera) |
|
|
382 | (2) |
|
Pharmacotherapy of Narcolepsy |
|
|
384 | (2) |
|
Prototype Drug: Modafinil (Provigil) |
|
|
384 | (2) |
|
|
|
386 | (6) |
|
|
|
386 | (1) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Central Nervous System Stimulants |
|
|
387 | (5) |
|
25 Pharmacotherapy of Severe Pain and Migraines |
|
|
392 | (30) |
|
General Principles of Pain Management |
|
|
393 | (5) |
|
Pain Management with Opioids |
|
|
398 | (8) |
|
Prototype Drug: Morphine Sulfate (Astramorph PF, Duramorph RF, Roxanol, Others) |
|
|
402 | (4) |
|
Pain Management with Nonopioids |
|
|
406 | (6) |
|
Prototype Drug: Tramadol (Ultram, Others) |
|
|
406 | (2) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Pain |
|
|
408 | (4) |
|
Pharmacotherapy with Opioid Antagonists |
|
|
412 | (1) |
|
Pharmacotherapy of Migraines |
|
|
413 | (9) |
|
Prototype Drug: Sumatriptan (Imitrex, Onzetra) |
|
|
415 | (2) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Migraines |
|
|
417 | (5) |
|
26 Anesthetics and Anesthesia Adjuncts |
|
|
422 | (25) |
|
|
|
423 | (1) |
|
Principles of General Anesthesia |
|
|
423 | (1) |
|
|
|
424 | (6) |
|
Prototype Drug: Fentanyl (Sublimaze) |
|
|
425 | (2) |
|
Prototype Drug: Midazolam (Versed) |
|
|
427 | (1) |
|
Prototype Drug: Propofol (Diprivan) |
|
|
428 | (2) |
|
|
|
430 | (3) |
|
Prototype Drug: Nitrous Oxide |
|
|
430 | (2) |
|
Prototype Drug: Isoflurane (Forane) |
|
|
432 | (1) |
|
|
|
433 | (8) |
|
Connections: Nursing Practice Application Patients Receiving General Anesthesia |
|
|
434 | (4) |
|
Prototype Drug: Procaine (Novocaine) |
|
|
438 | (1) |
|
Prototype Drug: Lidocaine (Anestacon, Xylocaine, Zingo, Others) |
|
|
439 | (2) |
|
|
|
441 | (6) |
|
Connections: Nursing Practice Application Patients Receiving Local Anesthesia |
|
|
442 | (5) |
|
27 Pharmacology of Substance Abuse |
|
|
447 | (27) |
|
Fundamental Concepts of Substance Abuse |
|
|
448 | (4) |
|
Legislation of Controlled Substances |
|
|
449 | (1) |
|
|
|
449 | (2) |
|
|
|
451 | (1) |
|
Central Nervous System Depressants |
|
|
452 | (6) |
|
Sedatives and Antianxiety Drugs |
|
|
452 | (1) |
|
|
|
453 | (2) |
|
Prototype Drug: Buprenorphine with Naloxone (Suboxone, Zubsolv, Others) |
|
|
454 | (1) |
|
|
|
455 | (4) |
|
Prototype Drug: Disulfiram (Antabuse) |
|
|
457 | (1) |
|
Marijuana and Related Substances |
|
|
458 | (1) |
|
|
|
459 | (2) |
|
LSD and Similar Hallucinogens |
|
|
459 | (1) |
|
Club Drugs and Miscellaneous Hallucinogens |
|
|
460 | (1) |
|
Central Nervous System Stimulants |
|
|
461 | (2) |
|
Amphetamines and Methylphenidate |
|
|
461 | (1) |
|
|
|
462 | (1) |
|
|
|
463 | (1) |
|
|
|
463 | (2) |
|
Prototype Drug: Varenicline (Chantix) |
|
|
464 | (1) |
|
|
|
465 | (2) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Substance Abuse Disorders |
|
|
466 | (1) |
|
|
|
467 | (7) |
| Unit 5 Pharmacology of the Cardiovascular System |
|
|
28 Review of the Cardiovascular System |
|
|
474 | (14) |
|
Structure and Function of the Cardiovascular System |
|
|
475 | (1) |
|
Functions and Properties of Blood |
|
|
475 | (3) |
|
Cardiac Structure and Function |
|
|
478 | (5) |
|
Hemodynamics and Blood Pressure |
|
|
483 | (5) |
|
29 Pharmacotherapy of Hyperlipidemia |
|
|
488 | (22) |
|
Types of Lipids and Lipoproteins |
|
|
489 | (3) |
|
Measurement and Control of Serum Lipids |
|
|
492 | (2) |
|
|
|
494 | (16) |
|
Prototype Drug: Atorvastatin (Lipitor) |
|
|
496 | (4) |
|
Prototype Drug: Cholestyramine (Questran) |
|
|
500 | (2) |
|
Prototype Drug: Gemfibrozil (Lopid) |
|
|
502 | (1) |
|
Miscellaneous Drugs for Dyslipidemias |
|
|
503 | (40) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Hyperlipidemia |
|
|
505 | (5) |
|
30 Pharmacotherapy with Calcium Channel Blockers |
|
|
510 | (13) |
|
Physiologic Role of Calcium Channels in Muscle Contraction |
|
|
511 | (1) |
|
Types of Calcium Channels |
|
|
512 | (1) |
|
Consequences of Calcium Channel Blockade |
|
|
513 | (1) |
|
Classification of Calcium Channel Blockers |
|
|
513 | (10) |
|
Prototype Drug: Nifedipine (Adalat CC, Procardia XL) |
|
|
515 | (2) |
|
Prototype Drug: Verapamil (Calan, Isoptin, Verelan) |
|
|
517 | (2) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Calcium Channel Blockers |
|
|
519 | (4) |
|
31 Drugs Affecting the Renin-Angiotensin-Aldosterone System |
|
|
523 | (16) |
|
Components of the Renin-Angiotensin-Aldosterone System |
|
|
524 | (2) |
|
Physiologic Actions of the Renin-Angiotensin-Aldosterone System |
|
|
526 | (1) |
|
Drugs Affecting the Renin-Angiotensin-Aldosterone System |
|
|
527 | (12) |
|
Prototype Drug: Lisinopril (Prinivil, Zestril) |
|
|
529 | (3) |
|
Prototype Drug: Losartan (Cozaar) |
|
|
532 | (2) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers |
|
|
534 | (5) |
|
32 Diuretic Therapy and the Pharmacotherapy of Chronic Kidney Disease |
|
|
539 | (22) |
|
Review of Renal Physiology |
|
|
540 | (1) |
|
Pharmacotherapy for Patients with Chronic Kidney Disease |
|
|
541 | (2) |
|
|
|
543 | (18) |
|
Loop (High-Ceiling) Diuretics |
|
|
545 | (3) |
|
Prototype Drug: Furosemide (Lasix) |
|
|
546 | (2) |
|
Thiazide and Thiazide-Like Diuretics |
|
|
548 | (2) |
|
Prototype Drug: Hydrochlorothiazide (Microzide) |
|
|
549 | (1) |
|
Potassium-Sparing Diuretics |
|
|
550 | (2) |
|
Prototype Drug: Spironolactone (Aldactone) |
|
|
551 | (1) |
|
|
|
552 | (2) |
|
Prototype Drug: Mannitol (Osmitrol) |
|
|
553 | (1) |
|
Carbonic Anhydrase Inhibitors |
|
|
554 | (31) |
|
Prototype Drug: Acetazolamide (Diamox) |
|
|
554 | (1) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Diuretics |
|
|
555 | (6) |
|
33 Pharmacotherapy of Fluid Imbalance, Electrolyte, and Acid-Base Disorders |
|
|
561 | (21) |
|
Principles of Fluid Balance |
|
|
562 | (1) |
|
|
|
563 | (5) |
|
Prototype Drug: Normal Serum Albumin (Albuminar, Plasbumin, Others) |
|
|
565 | (1) |
|
Prototype Drug: 5% Dextrose in Water (D5W) |
|
|
566 | (1) |
|
Prototype Drug: Dextran 40 (Gentran 40, Others) |
|
|
567 | (1) |
|
Physiology of Electrolytes |
|
|
568 | (1) |
|
Pharmacotherapy of Electrolyte Imbalances |
|
|
569 | (6) |
|
Prototype Drug: Sodium Chloride (NaCl) |
|
|
571 | (1) |
|
Prototype Drug: Potassium Chloride (KCl) |
|
|
572 | (2) |
|
Prototype Drug: Magnesium Sulfate (MgSO4) |
|
|
574 | (1) |
|
Pharmacotherapy of Acid-Base Imbalances |
|
|
575 | (7) |
|
Prototype Drug: Sodium Bicarbonate |
|
|
576 | (1) |
|
Prototype Drug: Ammonium Chloride |
|
|
577 | (1) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Fluid and Electrolyte Imbalances |
|
|
578 | (4) |
|
34 Pharmacotherapy of Hypertension |
|
|
582 | (20) |
|
Etiology and Pathogenesis of Hypertension |
|
|
583 | (1) |
|
Nonpharmacologic Management of Hypertension |
|
|
584 | (1) |
|
Guidelines for the Management of Hypertension |
|
|
584 | (1) |
|
Pharmacotherapy of Hypertension |
|
|
585 | (3) |
|
Drugs for Initial Hypertension Therapy |
|
|
586 | (1) |
|
Adding Drugs to the Antihypertensive Regimen |
|
|
587 | (1) |
|
Enhancing Patient Adherence |
|
|
587 | (1) |
|
Antihypertensives in African Americans |
|
|
588 | (1) |
|
Drug Classes for Hypertension |
|
|
588 | (6) |
|
Prototype Drug: Hydralazine |
|
|
593 | (1) |
|
Management of Hypertensive Emergency |
|
|
594 | (8) |
|
Prototype Drug: Nitroprtisside Sodium (Nitropress) |
|
|
595 | (1) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Direct Vasodilators |
|
|
596 | (6) |
|
35 Pharmacotherapy of Angina Pectoris and Myocardial Infarction |
|
|
602 | (20) |
|
Pathophysiology of Myocardial Ischemia |
|
|
603 | (1) |
|
|
|
603 | (1) |
|
|
|
603 | (1) |
|
Etiology of Coronary Artery Disease |
|
|
604 | (1) |
|
Pathophysiology of Angina Pectoris |
|
|
604 | (1) |
|
Nonpharmacologic Therapy of Coronary Artery Disease |
|
|
605 | (1) |
|
Pharmacologic Management of Angina Pectoris |
|
|
606 | (1) |
|
Drug Classes for Angina Pectoris |
|
|
607 | (5) |
|
Prototype Drug: Nitroglycerin (Nitrostat, Nitro-Bid, Nitro-Dur, Others) |
|
|
609 | (2) |
|
Prototype Drug: Atenolol (Tenormin) |
|
|
611 | (1) |
|
Pathophysiology of Myocardial Infarction |
|
|
612 | (1) |
|
Pharmacologic Management of Myocardial Infarction |
|
|
613 | (9) |
|
|
|
614 | (1) |
|
Anticoagulants and Antiplatelet Drugs |
|
|
614 | (2) |
|
|
|
616 | (1) |
|
Beta-Adrenergic Antagonists |
|
|
616 | (1) |
|
Angiotensin-Converting Enzyme Inhibitors |
|
|
616 | (1) |
|
|
|
617 | (6) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Organic Nitrates for Angina and Myocardial Infarction |
|
|
617 | (5) |
|
36 Pharmacotherapy of Heart Failure |
|
|
622 | (19) |
|
Etiology of Heart Failure |
|
|
623 | (1) |
|
Pathophysiology of Heart Failure |
|
|
623 | (3) |
|
|
|
624 | (1) |
|
Activation of the Sympathetic Nervous System |
|
|
625 | (1) |
|
Increased Plasma Volume and Preload |
|
|
625 | (1) |
|
Natriuretic Peptides and Neurohumoral Factors |
|
|
625 | (1) |
|
Pharmacologic Management of Heart Failure |
|
|
626 | (1) |
|
|
|
627 | (14) |
|
Prototype Drug: Digoxin (Lanoxin, Lanoxicaps) |
|
|
632 | (3) |
|
Prototype Drug: Milrinone (Primacor) |
|
|
635 | (1) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Heart Failure |
|
|
635 | (6) |
|
37 Pharmacotherapy of Dysrhythmias |
|
|
641 | (20) |
|
|
|
642 | (1) |
|
Phases and Measurement of the Cardiac Action Potential |
|
|
642 | (3) |
|
Classification of Dysrhythmias |
|
|
645 | (1) |
|
General Principles of Dysrhythmia Management |
|
|
646 | (1) |
|
|
|
646 | (15) |
|
Sodium Channel Blockers: Class I |
|
|
647 | (5) |
|
Prototype Drug: Procainamide |
|
|
649 | (3) |
|
Beta-Adrenergic Antagonists: Class II |
|
|
652 | (1) |
|
Potassium Channel Blockers: Class III |
|
|
653 | (2) |
|
Prototype Drug: Amiodarone (Pacerone) |
|
|
653 | (2) |
|
Calcium Channel Blockers: Class IV |
|
|
655 | (1) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Dysrhythmias |
|
|
656 | (1) |
|
Miscellaneous Antidysrhythmics |
|
|
656 | (5) |
|
38 Pharmacotherapy of Coagulation Disorders |
|
|
661 | (30) |
|
|
|
662 | (2) |
|
Overview of Coagulation Modifiers |
|
|
664 | (1) |
|
|
|
665 | (9) |
|
|
|
666 | (3) |
|
Prototype Drug: Warfarin (Coumadin) |
|
|
669 | (2) |
|
Prototype Drug: Dabigatran (Pradaxa) |
|
|
671 | (1) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Anticoagulants |
|
|
672 | (2) |
|
|
|
674 | (5) |
|
Prototype Drug: Clopidogrel (Plavix) |
|
|
675 | (2) |
|
Prototype Drug: Abciximab (ReoPro) |
|
|
677 | (2) |
|
Drugs for Intermittent Claudication |
|
|
679 | (1) |
|
|
|
680 | (4) |
|
Prototype Drug: Alteplase (Activase) |
|
|
681 | (1) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Thrombolytics |
|
|
682 | (2) |
|
|
|
684 | (2) |
|
Prototype Drug: Aminocaproic Acid (Amicar) |
|
|
684 | (2) |
|
|
|
686 | (5) |
|
39 Pharmacotherapy of Hematopoietic Disorders |
|
|
691 | (23) |
|
Physiology of Hematopoiesis |
|
|
692 | (1) |
|
Hematopoietic Growth Factors |
|
|
692 | (10) |
|
Prototype Drug: Epoetin Alfa (Epogen, Procrit) |
|
|
693 | (3) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Erythropoietin |
|
|
696 | (1) |
|
Prototype Drug: Filgrastim (Granix, Neupogen, Zarxio) |
|
|
697 | (2) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Colony-Stimulating Factors |
|
|
699 | (1) |
|
Prototype Drug: Oprelvekin (Neumega) |
|
|
700 | (2) |
|
Classification of Anemias |
|
|
702 | (1) |
|
|
|
703 | (11) |
|
Prototype Drug: Ferrous Sulfate (Feosol, Feostat, Others) |
|
|
705 | (3) |
|
Prototype Drug: Cyanocobalamin (Nascobal) |
|
|
708 | (6) |
| Unit 6 Pharmacology of Body Defenses |
|
|
40 Review of Body Defenses and the Immune System |
|
|
714 | (9) |
|
Organization of the Lymphatic System |
|
|
715 | (1) |
|
Innate (Nonspecific) Body Defenses |
|
|
715 | (4) |
|
|
|
718 | (1) |
|
Specific (Adaptive) Body Defenses |
|
|
719 | (4) |
|
|
|
720 | (1) |
|
Cell-Mediated Immune Response |
|
|
720 | (3) |
|
41 Pharmacotherapy of Inflammation and Fever |
|
|
723 | (18) |
|
Pathophysiology of Inflammation and Fever |
|
|
724 | (1) |
|
Pharmacotherapy of Inflammation |
|
|
724 | (1) |
|
Nonsteroidal Anti-Inflammatory Drugs |
|
|
725 | (10) |
|
|
|
725 | (5) |
|
Prototype Drug: Aspirin (Acetylsalicylic Acid) |
|
|
728 | (2) |
|
|
|
730 | (3) |
|
Prototype Drug: Ibuprofen (Advil, Motrin, Others) |
|
|
731 | (2) |
|
Cyclooxygenase-2 Inhibitors |
|
|
733 | (33) |
|
Prototype Drug: Celecoxib (Celebrex) |
|
|
734 | (1) |
|
Antipyretic and Analgesic Drugs |
|
|
735 | (6) |
|
Prototype Drug: Acetaminophen (Tylenol) |
|
|
735 | (2) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Inflammation and Fever |
|
|
737 | (4) |
|
42 Immunostimulants and Immunosuppressants |
|
|
741 | (21) |
|
|
|
743 | (4) |
|
Prototype Drug: Interferon Alfa-2b (Intron A) |
|
|
743 | (3) |
|
Prototype Drug: Aldesleukin (Proleukin) |
|
|
746 | (1) |
|
|
|
747 | (15) |
|
Prototype Drug: Cyclosporine (Gengraf, Neoral, Sandimmune) |
|
|
751 | (2) |
|
Prototype Drug: Azathioprine (Azasan, Imuran) |
|
|
753 | (2) |
|
Prototype Drug: Basiliximab (Simulect) |
|
|
755 | (2) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Immunomodulators |
|
|
757 | (5) |
|
|
|
762 | (24) |
|
|
|
763 | (1) |
|
Vaccines and the Immune System |
|
|
763 | (1) |
|
|
|
764 | (1) |
|
General Principles of Vaccine Administration |
|
|
765 | (1) |
|
Active Immunity: Bacterial Immunizations |
|
|
766 | (3) |
|
|
|
766 | (1) |
|
Pertussis (Whooping Cough) |
|
|
766 | (2) |
|
|
|
768 | (1) |
|
|
|
768 | (1) |
|
|
|
769 | (1) |
|
Active Immunity: Viral Immunizations |
|
|
769 | (7) |
|
|
|
769 | (2) |
|
Prototype Drug: Hepatitis B Vaccine (Engerix-B, Recombivax HB) |
|
|
770 | (1) |
|
|
|
771 | (1) |
|
|
|
771 | (1) |
|
|
|
772 | (1) |
|
Measles, Mumps, and Rubella |
|
|
772 | (1) |
|
|
|
773 | (1) |
|
|
|
774 | (1) |
|
|
|
775 | (1) |
|
|
|
776 | (1) |
|
|
|
776 | (10) |
|
Prototype Drug: Rho(D) Immune Globulin (RhoGAM) |
|
|
776 | (3) |
|
Connections: Nursing Practice Application Patients Receiving Immunizations |
|
|
779 | (7) |
| Unit 7 Pharmacology of the Respiratory System and Allergy |
|
|
44 Pharmacotherapy of Asthma and Other Pulmonary Disorders |
|
|
786 | (24) |
|
Physiology of the Lower Respiratory Tract |
|
|
787 | (1) |
|
Pathophysiology of Asthma |
|
|
788 | (1) |
|
Administration of Pulmonary Drugs via Inhalation |
|
|
788 | (2) |
|
Principles of Asthma Pharmacotherapy |
|
|
790 | (13) |
|
Prototype Drug: Albuterol (Proventil HFA, Ventolin HFA, VoSpire ER) |
|
|
792 | (4) |
|
Prototype Drug: Ipratropium (Atrovent) |
|
|
796 | (1) |
|
Prototype Drug: Beclomethasone (Beconase AQ, Qvar) |
|
|
797 | (2) |
|
|
|
799 | (1) |
|
Prototype Drug: Montelukast (Singulair) |
|
|
800 | (2) |
|
Prototype Drug: Theophylline |
|
|
802 | (1) |
|
Chronic Obstructive Pulmonary Disease |
|
|
803 | (7) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Asthma and COPD |
|
|
804 | (6) |
|
45 Pharmacotherapy of Allergic Rhinitis and the Common Cold |
|
|
810 | (24) |
|
Physiology of the Upper Respiratory Tract |
|
|
811 | (1) |
|
Pathophysiology of Allergic Rhinitis |
|
|
812 | (1) |
|
Pharmacotherapy of Allergic Rhinitis |
|
|
813 | (9) |
|
Prototype Drug: Fexofenadine (Allegra) |
|
|
816 | (2) |
|
Prototype Drug: Fluticasone (Flonase, Veramyst) |
|
|
818 | (1) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Antihistamines |
|
|
819 | (3) |
|
|
|
822 | (2) |
|
Prototype Drug: Pseudoephedrine (Sudafed) |
|
|
823 | (1) |
|
Drugs for the Common Cold |
|
|
824 | (1) |
|
|
|
825 | (1) |
|
Prototype Drug: Dextromethorphan (Delsym, Robitussin DM, Others) |
|
|
826 | (1) |
|
Expectorants and Mucolytics |
|
|
826 | (8) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Symptomatic Cough and Cold Relief |
|
|
827 | (7) |
| Unit 8 Pharmacology of Infectious and Neoplastic Diseases |
|
|
46 Basic Principles of Anti-Infective Pharmacotherapy |
|
|
834 | (14) |
|
Pathogenicity and Virulence |
|
|
835 | (1) |
|
Describing and Classifying Bacteria |
|
|
836 | (1) |
|
Classification of Anti-Infectives |
|
|
836 | (2) |
|
Mechanisms of Action of Anti-Infectives |
|
|
838 | (1) |
|
Inhibition of Cell Wall Synthesis |
|
|
838 | (1) |
|
Inhibition of Protein Synthesis |
|
|
838 | (1) |
|
Disruption of the Plasma Cell Membrane |
|
|
839 | (1) |
|
Inhibition of Nucleic Acid Synthesis |
|
|
839 | (1) |
|
Inhibition of Metabolic Pathways (Antimetabolites) |
|
|
839 | (1) |
|
Other Mechanisms of Action |
|
|
839 | (1) |
|
|
|
839 | (5) |
|
|
|
839 | (1) |
|
|
|
840 | (1) |
|
Prevention of Resistant Strains |
|
|
841 | (3) |
|
Indications and Selection of Specific Anti-Infectives |
|
|
844 | (1) |
|
Host Factors Affecting Anti-Infective Selection |
|
|
844 | (1) |
|
|
|
845 | (1) |
|
|
|
845 | (1) |
|
|
|
845 | (1) |
|
|
|
845 | (1) |
|
|
|
845 | (3) |
|
47 Antibiotics Affecting the Bacterial Cell Wall |
|
|
848 | (20) |
|
Structure of Bacterial Cell Walls |
|
|
849 | (1) |
|
|
|
850 | (6) |
|
|
|
852 | (2) |
|
Prototype Drug: Penicillin G |
|
|
852 | (2) |
|
Broad-Spectrum Penicillins (Aminopenicillins) |
|
|
854 | (1) |
|
Prototype Drug: Ampicillin |
|
|
854 | (1) |
|
Extended-Spectrum (Antipseudomonal) Penicillins |
|
|
855 | (1) |
|
Penicillinase-Resistant (Antistaphylococcal) Penicillins |
|
|
855 | (1) |
|
|
|
856 | (3) |
|
Prototype Drug: Cefazolin (Ancef, Kefzol) |
|
|
858 | (1) |
|
|
|
859 | (3) |
|
Prototype Drug: Imipenem-Cilastatin (Primaxin) |
|
|
860 | (2) |
|
Miscellaneous Cell Wall Inhibitors |
|
|
862 | (6) |
|
Prototype Drug: Vancomycin (Vancocin) |
|
|
862 | (1) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with a Penicillin, Cephalosporin, or Vancomycin Antibiotic |
|
|
863 | (5) |
|
48 Antibiotics Affecting Bacterial Protein Synthesis |
|
|
868 | (19) |
|
Mechanisms of Antibiotic Inhibition of Bacterial Protein Synthesis |
|
|
869 | (1) |
|
|
|
870 | (4) |
|
Prototype Drug: Tetracycline (Sumycin, Others) |
|
|
872 | (2) |
|
|
|
874 | (2) |
|
Prototype Drug: Erythromycin (EryC, Erythrocin, Others) |
|
|
875 | (1) |
|
|
|
876 | (4) |
|
Prototype Drug: Gentamicin (Garamycin, Others) |
|
|
878 | (2) |
|
Miscellaneous Inhibitors of Bacterial Protein Synthesis |
|
|
880 | (7) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with a Tetracycline, Macrolide, or Aminoglycoside Antibiotic |
|
|
882 | (5) |
|
49 Fluoroquinolones and Miscellaneous Antibacterials |
|
|
887 | (13) |
|
Bacterial DNA Replication |
|
|
888 | (1) |
|
Inhibition of DNA Replication |
|
|
888 | (1) |
|
|
|
889 | (4) |
|
|
|
890 | (11) |
|
Prototype Drug: Ciprofloxacin (Cipro) |
|
|
891 | (2) |
|
Miscellaneous Antibacterials |
|
|
893 | (7) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Fluoroquinolones |
|
|
895 | (5) |
|
50 Sulfonamides and the Pharmacotherapy of Urinary Tract Infections |
|
|
900 | (15) |
|
Pathophysiology of Urinary Tract Infections |
|
|
901 | (1) |
|
Pharmacotherapy of Urinary Tract Infections |
|
|
901 | (3) |
|
Acute Uncomplicated Cystitis |
|
|
902 | (1) |
|
Complicated Urinary Tract Infection |
|
|
902 | (1) |
|
|
|
903 | (1) |
|
|
|
903 | (1) |
|
|
|
903 | (1) |
|
Patients with Recurring Urinary Tract Infections |
|
|
904 | (1) |
|
|
|
904 | (4) |
|
|
|
906 | (12) |
|
Prototype Drug: Trimethoprim- Sulfamethoxazole (Bactrim, Septra) |
|
|
907 | (1) |
|
|
|
908 | (7) |
|
Prototype Drug: Nitrofurantoin (Furadantin) and Nitrofurantoin Macrocrystals (Macrobid, Macrodantin) |
|
|
908 | (2) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Urinary Tract Infection |
|
|
910 | (5) |
|
51 Pharmacotherapy of Mycobacterial Infections |
|
|
915 | (19) |
|
Types of Mycobacterial Infections |
|
|
916 | (1) |
|
Pathogenesis and Diagnosis of Tuberculosis |
|
|
916 | (2) |
|
Pharmacotherapy of Tuberculosis |
|
|
918 | (10) |
|
|
|
919 | (2) |
|
Patients Who Are HIV Positive |
|
|
921 | (1) |
|
|
|
921 | (1) |
|
Chemoprophylaxis Patients |
|
|
921 | (107) |
|
Prototype Drug: Isoniazid (INH) |
|
|
922 | (5) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Tuberculosis |
|
|
927 | (1) |
|
|
|
928 | (2) |
|
Prototype Drug: Dapsone (DDS) |
|
|
929 | (1) |
|
Drugs for Mycobacterium avium Complex Infections |
|
|
930 | (4) |
|
52 Pharmacotherapy of Fungal Infections |
|
|
934 | (18) |
|
Characteristics of Fungi and Fungal Infections |
|
|
935 | (3) |
|
Drugs for Systemic Fungal Infections |
|
|
938 | (3) |
|
Prototype Drug: Amphotericin B Deoxycholate (Fungizone) |
|
|
939 | (2) |
|
Drugs for Both Systemic and Superficial Fungal Infections |
|
|
941 | (2) |
|
Prototype Drug: Fluconazole (Diflucan) |
|
|
941 | (2) |
|
Drugs for Superficial Fungal Infections |
|
|
943 | (9) |
|
Prototype Drug: Nystatin (Nystop) |
|
|
947 | (1) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Antifungals |
|
|
948 | (4) |
|
53 Pharmacotherapy of Protozoan and Helminthic Infections |
|
|
952 | (23) |
|
Classification and Pathogenesis of Protozoan Infections |
|
|
953 | (1) |
|
|
|
954 | (4) |
|
Prototype Drug: Chloroquine (Aralen) |
|
|
956 | (2) |
|
Drugs for Nonmalarial Protozoan Infections |
|
|
958 | (7) |
|
Prototype Drug: Metronidazole (Flagyl) |
|
|
960 | (4) |
|
Prototype Drug: Pyrimethamine (Daraprim) |
|
|
964 | (1) |
|
Classification and Pathogenesis of Helminthic Infections |
|
|
965 | (3) |
|
Drugs for Helminthic Infections |
|
|
968 | (7) |
|
Prototype Drug: Mebendazole (Vermox) |
|
|
968 | (2) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Protozoan and Helminthic Infections |
|
|
970 | (5) |
|
54 Pharmacotherapy of Non-HIV Viral Infections |
|
|
975 | (21) |
|
Characteristics of Viruses |
|
|
976 | (2) |
|
Pharmacotherapy of Non-HIV Viral Infections |
|
|
978 | (1) |
|
|
|
979 | (3) |
|
Prototype Drug: Acyclovir (Zovirax) |
|
|
980 | (2) |
|
Drugs for Influenza Viruses |
|
|
982 | (3) |
|
Prototype Drug: Amantadine (Symmetrel) |
|
|
984 | (1) |
|
Drugs for Hepatitis Viruses |
|
|
985 | (11) |
|
Prototype Drug: Tenofovir (Vemlidy, Viread) |
|
|
989 | (3) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Antivirals for Non-HIV Viral Infections |
|
|
992 | (4) |
|
55 Pharmacotherapy of HIV Infection and AIDS |
|
|
996 | (24) |
|
Pathogenesis of HIV Infection |
|
|
997 | (2) |
|
General Principles of HIV Pharmacotherapy |
|
|
999 | (2) |
|
Classification of Antiretroviral Drugs |
|
|
1001 | (2) |
|
|
|
1003 | (7) |
|
Prototype Drug: Zidovudine (AZT, Retrovir) |
|
|
1004 | (2) |
|
Prototype Drug: Efavirenz (Sustiva) |
|
|
1006 | (2) |
|
Prototype Drug: Lopinavir with Ritonavir (Kaletra) |
|
|
1008 | (2) |
|
Prophylaxis of HIV Infections |
|
|
1010 | (5) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Antiretrovirals |
|
|
1011 | (4) |
|
Pharmacotherapy of Opportunistic Infections Associated with HIV and AIDS |
|
|
1015 | (5) |
|
56 Basic Principles of Antineoplastic Therapy |
|
|
1020 | (16) |
|
Characteristics of Cancer |
|
|
1021 | (1) |
|
|
|
1022 | (1) |
|
Detection and Prevention of Cancer |
|
|
1023 | (1) |
|
|
|
1023 | (1) |
|
Staging and Grading of Cancer |
|
|
1024 | (1) |
|
The Cell Cycle and Growth Fraction |
|
|
1025 | (2) |
|
|
|
1027 | (1) |
|
Improving the Success of Chemotherapy |
|
|
1028 | (1) |
|
|
|
1028 | (1) |
|
|
|
1028 | (1) |
|
|
|
1028 | (1) |
|
Toxicity of Antineoplastic Drugs |
|
|
1029 | (7) |
|
|
|
1029 | (1) |
|
|
|
1030 | (1) |
|
|
|
1031 | (1) |
|
|
|
1031 | (1) |
|
|
|
1031 | (1) |
|
|
|
1031 | (1) |
|
|
|
1032 | (1) |
|
|
|
1032 | (4) |
|
57 Pharmacotherapy of Neoplasia |
|
|
1036 | (38) |
|
Classification of Antineoplastic Drugs |
|
|
1037 | (1) |
|
Antineoplastic Medications |
|
|
1037 | (32) |
|
|
|
1037 | (6) |
|
Prototype Drug: Cydophosphamide (Cytoxan) |
|
|
1038 | (5) |
|
|
|
1043 | (5) |
|
Prototype Drug: Methotrexate (MTX, Rheumatrex, Trexall) |
|
|
1044 | (4) |
|
|
|
1048 | (3) |
|
Prototype Drug: Doxorubicin (Adriamycin) |
|
|
1048 | (3) |
|
Hormones and Hormone Antagonists |
|
|
1051 | (5) |
|
Prototype Drug: Tamoxifen |
|
|
1053 | (3) |
|
|
|
1056 | (7) |
|
Prototype Drug: Vincristine (Marqibo, Oncovin) |
|
|
1057 | (3) |
|
Connections: Nursing Practice Application Patients Receiving Cancer Chemotherapy |
|
|
1060 | (3) |
|
Biologic Response Modifiers and Targeted Therapies |
|
|
1063 | (3) |
|
Miscellaneous Antineoplastics |
|
|
1066 | (3) |
|
Drugs for Reducing Adverse Effects |
|
|
1069 | (1) |
|
Preparing and Administering Antineoplastics |
|
|
1069 | (5) |
| Unit 9 Pharmacology of the Gastrointestinal System |
|
|
58 Review of the Gastrointestinal System |
|
|
1074 | (8) |
|
Overview of the Digestive System |
|
|
1075 | (1) |
|
Physiology of the Upper Gastrointestinal Tract |
|
|
1075 | (2) |
|
Physiology of the Lower Gastrointestinal Tract |
|
|
1077 | (1) |
|
Physiology of the Accessory Organs of Digestion |
|
|
1077 | (2) |
|
Regulation of Digestive Processes |
|
|
1079 | (1) |
|
Nutrient Categories and Metabolism |
|
|
1080 | (2) |
|
59 Pharmacotherapy of Peptic Ulcer Disease |
|
|
1082 | (21) |
|
Physiology of the Upper Gastrointestinal Tract |
|
|
1083 | (1) |
|
Etiology and Pathogenesis of Peptic Ulcer Disease |
|
|
1084 | (2) |
|
Etiology and Pathogenesis of Gastroesophageal Reflux Disease |
|
|
1086 | (2) |
|
Pharmacotherapy of Peptic Ulcer Disease and Gastroesophageal Reflux Disease |
|
|
1088 | (15) |
|
Pharmacotherapy with Proton Pump Inhibitors |
|
|
1088 | (4) |
|
Prototype Drug: Omeprazole (Prilosec) |
|
|
1090 | (2) |
|
Pharmacotherapy with H2-Receptor Antagonists |
|
|
1092 | (2) |
|
Prototype Drug: Ranitidine (Zantac) |
|
|
1093 | (1) |
|
Pharmacotherapy with Antacids |
|
|
1094 | (2) |
|
Prototype Drug: Aluminum Hydroxide (AlternaGEL, Others) |
|
|
1095 | (1) |
|
Pharmacotherapy of Helicobacter pylori Infection |
|
|
1096 | (1) |
|
Miscellaneous Drugs Used for Peptic Ulcer Disease and Gastroesophageal Reflux Disease |
|
|
1097 | (37) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Peptic Ulcer Disease |
|
|
1098 | (5) |
|
60 Pharmacotherapy of Bowel Disorders and Other Gastrointestinal Conditions |
|
|
1103 | (27) |
|
Pathophysiology of Constipation |
|
|
1104 | (1) |
|
Pharmacotherapy with Laxatives |
|
|
1105 | (3) |
|
Prototype Drug: Psyllium Mucilloid (Metamucil, Naturacil, Others) |
|
|
1107 | (1) |
|
Pathophysiology of Diarrhea |
|
|
1108 | (1) |
|
Pharmacotherapy of Diarrhea |
|
|
1109 | (3) |
|
Prototype Drug: Diphenoxylate with Atropine (Lomotil) |
|
|
1110 | (1) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Laxatives or Antidiarrheals |
|
|
1111 | (1) |
|
Pharmacotherapy of Inflammatory Bowel Disease |
|
|
1112 | (5) |
|
Prototype Drug: Sulfasalazine (Azulfidine) |
|
|
1115 | (2) |
|
Pharmacotherapy of Irritable Bowel Syndrome |
|
|
1117 | (1) |
|
Pathophysiology of Nausea and Vomiting |
|
|
1118 | (1) |
|
Pharmacotherapy of Nausea and Vomiting |
|
|
1119 | (4) |
|
Prototype Drug: Ondansetron (Zofran, Zuplenz) |
|
|
1123 | (1) |
|
Pharmacotherapy of Pancreatitis |
|
|
1123 | (7) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Antiemetics |
|
|
1124 | (2) |
|
Prototype Drug: Pancrelipase (Creon, Pancreaze, Zenpep) |
|
|
1126 | (4) |
|
|
|
1130 | (17) |
|
Role of Vitamins in Health and Disease |
|
|
1131 | (1) |
|
|
|
1132 | (1) |
|
Recommended Dietary Allowance |
|
|
1133 | (1) |
|
|
|
1134 | (3) |
|
|
|
1134 | (1) |
|
Vitamin D (Calcijex, Rocaltrol) |
|
|
1135 | (1) |
|
Vitamin E (Aquasol E, Vita-Plus E, Others) |
|
|
1136 | (1) |
|
|
|
1136 | (1) |
|
|
|
1137 | (4) |
|
|
|
1137 | (1) |
|
|
|
1138 | (1) |
|
|
|
1138 | (1) |
|
|
|
1138 | (1) |
|
Folic Acid (Folate): Vitamin B9 |
|
|
1139 | (1) |
|
Cyanocobalamin: Vitamin B12 |
|
|
1140 | (1) |
|
|
|
1140 | (1) |
|
|
|
1141 | (6) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Vitamin or Mineral Supplements |
|
|
1143 | (4) |
|
62 Enteral and Parenteral Nutrition |
|
|
1147 | (15) |
|
|
|
1149 | (3) |
|
|
|
1149 | (1) |
|
Elements of Enteral Nutrition |
|
|
1149 | (1) |
|
Complications of Enteral Therapy |
|
|
1150 | (2) |
|
Drug and Food Interactions |
|
|
1152 | (1) |
|
|
|
1152 | (10) |
|
Components of Total Parenteral Nutrition Solutions |
|
|
1153 | (1) |
|
Complications of Parenteral Therapy |
|
|
1154 | (1) |
|
Drug and Food Interactions |
|
|
1155 | (52) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Enteral and Parenteral Nutrition |
|
|
1156 | (6) |
|
63 Weight Reduction Strategies and the Pharmacotherapy of Obesity |
|
|
1162 | (14) |
|
|
|
1163 | (1) |
|
|
|
1164 | (1) |
|
|
|
1164 | (1) |
|
Nonpharmacologic Therapies for Obesity |
|
|
1165 | (1) |
|
Pharmacotherapy of Obesity |
|
|
1166 | (5) |
|
Prototype Drug: Orlistat (Alli, Xenical) |
|
|
1168 | (3) |
|
Adjuncts to Obesity Therapy |
|
|
1171 | (5) |
| Unit 10 Pharmacology of the Endocrine System |
|
|
64 Review of the Endocrine System |
|
|
1176 | (7) |
|
Overview of the Endocrine System |
|
|
1177 | (1) |
|
|
|
1177 | (1) |
|
Negative Feedback Mechanisms |
|
|
1178 | (2) |
|
|
|
1180 | (3) |
|
65 Hypothalamic and Pituitary Drugs |
|
|
1183 | (17) |
|
Functions of the Hypothalamus |
|
|
1184 | (1) |
|
Functions of the Pituitary Gland |
|
|
1185 | (1) |
|
Pharmacotherapy of Growth Hormone Disorders |
|
|
1186 | (7) |
|
Prototype Drug: Somatropin (Genotropin, Humatrope, Norditropin, Nutropin, Saizen, Serostim, Zorbtive) |
|
|
1188 | (2) |
|
Prototype Drug: Octreotide (Sandostatin) |
|
|
1190 | (2) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Growth Hormone |
|
|
1192 | (1) |
|
Pharmacotherapy of Antidiuretic Hormone Disorders |
|
|
1193 | (7) |
|
Prototype Drug: Desmopressin (DDAVP, Noctiva, Stimate) |
|
|
1194 | (2) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Antidiuretic Hormone |
|
|
1196 | (4) |
|
66 Pharmacotherapy of Diabetes Mellitus |
|
|
1200 | (29) |
|
Physiology of Serum Glucose Control |
|
|
1201 | (1) |
|
Pathophysiology of Diabetes Mellitus: Types of Diabetes |
|
|
1202 | (1) |
|
Symptoms and Diagnosis of Diabetes |
|
|
1203 | (1) |
|
Complications of Diabetes Mellitus |
|
|
1204 | (3) |
|
Prototype Drug: Glucagon (GlucaGen) |
|
|
1205 | (2) |
|
|
|
1207 | (4) |
|
|
|
1209 | (2) |
|
Prototype Drug: Human Regular Insulin (Humulin R, Novolin R) |
|
|
1209 | (2) |
|
Antidiabetic Drugs for Type 2 Diabetes |
|
|
1211 | (12) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Insulin |
|
|
1211 | (4) |
|
|
|
1215 | (2) |
|
Prototype Drug: Glyburide (DiaBeta, Glynase) |
|
|
1215 | (2) |
|
|
|
1217 | (1) |
|
Prototype Drug: Metformin (Glucophage, Glumetza, Others) |
|
|
1217 | (1) |
|
|
|
1218 | (1) |
|
Prototype Drug: Repaglinide (Prandin) |
|
|
1218 | (1) |
|
|
|
1219 | (1) |
|
Prototype Drug: Rosiglitazone (Avandia) |
|
|
1219 | (1) |
|
Alpha-Glucosidase Inhibitors |
|
|
1220 | (1) |
|
Prototype Drug: Acarbose (Precose) |
|
|
1220 | (1) |
|
|
|
1221 | (111) |
|
Prototype Drug: Sitagliptin (Januvia) |
|
|
1221 | (2) |
|
Miscellaneous Antidiabetic Drugs |
|
|
1223 | (6) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Type 2 Diabetes |
|
|
1223 | (6) |
|
67 Pharmacotherapy of Thyroid Disorders |
|
|
1229 | (16) |
|
Physiology of the Thyroid Gland |
|
|
1230 | (1) |
|
Diagnosis of Thyroid Disorders |
|
|
1231 | (1) |
|
Pathophysiology of Hypothyroid Disorders |
|
|
1232 | (1) |
|
Pharmacotherapy of Hypothyroid Disorders |
|
|
1233 | (4) |
|
Prototype Drug: Levothyroxine (Levothroid, Levoxyl, Synthroid, Unithroid) |
|
|
1233 | (2) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Thyroid Hormone Replacements |
|
|
1235 | (2) |
|
Pathophysiology of Hyperthyroid Disorders |
|
|
1237 | (1) |
|
Pharmacotherapy of Hyperthyroid Disorders |
|
|
1237 | (8) |
|
Prototype Drug: Propylthiouracil (PTU) |
|
|
1238 | (2) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Antithyroid Drugs |
|
|
1240 | (5) |
|
68 Corticosteroids and Drugs Affecting the Adrenal Cortex |
|
|
1245 | (17) |
|
Physiology of the Adrenal Gland |
|
|
1246 | (1) |
|
Overview of Corticosteroid Pharmacotherapy |
|
|
1247 | (1) |
|
Adverse Effects of Corticosteroids |
|
|
1248 | (2) |
|
Replacement Therapy with Corticosteroids |
|
|
1250 | (3) |
|
Prototype Drug: Hydrocortisone (Cortef, Solu-Cortef, Others) |
|
|
1252 | (1) |
|
Corticosteroids for Nonendocrine Conditions |
|
|
1253 | (4) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Systemic Corticosteroids |
|
|
1255 | (2) |
|
|
|
1257 | (1) |
|
Prototype Drug: Fludrocortisone |
|
|
1257 | (1) |
|
|
|
1258 | (4) |
|
69 Estrogens, Progestins, and Drugs Modifying Uterine Function |
|
|
1262 | (25) |
|
Hormonal Regulation of Female Reproductive Function |
|
|
1263 | (1) |
|
|
|
1263 | (4) |
|
Prototype Drug: Conjugated Estrogens (Cenestin, Enjuvia, Premarin) |
|
|
1265 | (2) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Estrogen |
|
|
1267 | (1) |
|
|
|
1267 | (4) |
|
Prototype Drug: Medroxyprogesterone (Depo-Provera, Depo-SubQ-Provera, Provera) |
|
|
1269 | (1) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Progestin |
|
|
1270 | (1) |
|
Hormone Replacement Therapy |
|
|
1271 | (2) |
|
Uterine Stimulants: Oxytocics |
|
|
1273 | (4) |
|
Prototype Drug: Oxytocin (Pitocin) |
|
|
1274 | (2) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Oxytocin (Pitocin) |
|
|
1276 | (1) |
|
Uterine Relaxants: Tocolytics |
|
|
1277 | (1) |
|
Pharmacotherapy of Female Infertility and Female Sexual Desire Disorder |
|
|
1278 | (9) |
|
Prototype Drug: Clomiphene (Clomid, Serophene) |
|
|
1281 | (6) |
|
70 Drugs for Modifying Conception |
|
|
1287 | (20) |
|
Options and Choices for Birth Control |
|
|
1288 | (1) |
|
Combination Oral Contraceptives |
|
|
1288 | (5) |
|
Prototype Drug: Estradiol and Norethindrone (Ortho-Novum, Others) |
|
|
1292 | (1) |
|
Adverse Effects of Combination Oral Contraceptives |
|
|
1293 | (2) |
|
Progestin-Only Oral Contraceptives |
|
|
1295 | (1) |
|
Long-Acting Reversible Contraceptives |
|
|
1295 | (3) |
|
|
|
1298 | (2) |
|
Prototype Drug: Nonoxynol-9 |
|
|
1298 | (1) |
|
Connections: Nursing Practice Application Patients Receiving Hormonal Contraceptives |
|
|
1299 | (1) |
|
|
|
1300 | (1) |
|
Drugs for Pharmacologic Abortion |
|
|
1301 | (6) |
|
Prototype Drug: Mifepristone (Mifeprex) |
|
|
1302 | (5) |
|
71 Drugs for Disorders and Conditions of the Male Reproductive System |
|
|
1307 | (21) |
|
Regulation of Male Reproductive Function |
|
|
1308 | (1) |
|
Pharmacotherapy with Androgens |
|
|
1308 | (5) |
|
Prototype Drug: Testosterone |
|
|
1311 | (1) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy with Androgens |
|
|
1312 | (1) |
|
|
|
1313 | (1) |
|
Etiology of Male Sexual Dysfunction |
|
|
1314 | (1) |
|
Pharmacotherapy of Male Infertility |
|
|
1315 | (1) |
|
Pharmacotherapy of Erectile Dysfunction |
|
|
1316 | (3) |
|
Prototype Drug: Sildenafil (Viagra) |
|
|
1317 | (2) |
|
Pathophysiology of Benign Prostatic Hyperplasia |
|
|
1319 | (2) |
|
Pharmacotherapy of Benign Prostatic Hyperplasia |
|
|
1321 | (7) |
|
Prototype Drug: Finasteride (Proscar) |
|
|
1322 | (1) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Benign Prostatic Hyperplasia |
|
|
1323 | (5) |
| Unit 11 Additional Drug Classes |
|
|
72 Pharmacotherapy of Bone and Joint Disorders |
|
|
1328 | (36) |
|
Role of Calcium in Body Homeostasis |
|
|
1329 | (1) |
|
Regulation of Calcium Balance |
|
|
1330 | (2) |
|
Pharmacotherapy of Calcium Imbalances |
|
|
1332 | (4) |
|
Treatment of Hypocalcemia |
|
|
1332 | (2) |
|
Prototype Drug: Calcium Salts |
|
|
1333 | (1) |
|
Treatment of Hypercalcemia |
|
|
1334 | (11) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Osteoporosis |
|
|
1335 | (1) |
|
Pathophysiology of Metabolic Bone Disease |
|
|
1336 | (2) |
|
Pharmacotherapy of Metabolic Bone Disease |
|
|
1338 | (7) |
|
Prototype Drug: Calcitriol (Calcijex, Rocaltrol) |
|
|
1338 | (2) |
|
Prototype Drug: Alendronate (Fosamax) |
|
|
1340 | (3) |
|
Prototype Drug: Raloxifene (Evista) |
|
|
1343 | (2) |
|
Pathophysiology and Pharmacotherapy of Joint Disorders |
|
|
1345 | (10) |
|
Prototype Drug: Adalimumab (Humira) |
|
|
1350 | (1) |
|
Other DMARDS for Rheumatoid Arthritis |
|
|
1351 | (16) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Rheumatoid Arthritis and Osteoarthritis |
|
|
1353 | (2) |
|
Pharmacotherapy of Gout and Hyperuricemia |
|
|
1355 | (9) |
|
Prototype Drug: Colchicine (Colcrys) |
|
|
1356 | (1) |
|
Prototype Drug: Allopurinol (Lopurin, Zyloprim) |
|
|
1357 | (2) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Gout |
|
|
1359 | (5) |
|
73 Pharmacotherapy of Dermatologic Disorders |
|
|
1364 | (25) |
|
Anatomy of the Integumentary System |
|
|
1365 | (2) |
|
Classification of Skin Disorders |
|
|
1367 | (1) |
|
Pharmacotherapy of Skin Infections |
|
|
1367 | (3) |
|
Scabicides and Pediculicides |
|
|
1368 | (2) |
|
Prototype Drug: Permethrin (Acticin, Elimite, Nix) |
|
|
1369 | (1) |
|
Pharmacotherapy of Acne and Rosacea |
|
|
1370 | (6) |
|
|
|
1370 | (3) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Lice or Mite Infestation |
|
|
1371 | (2) |
|
|
|
1373 | (5) |
|
Prototype Drug: Tretinoin (Avita, Retin-A, Others) |
|
|
1373 | (2) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Acne and Related Skin Conditions |
|
|
1375 | (1) |
|
Pharmacotherapy of Dermatitis |
|
|
1376 | (2) |
|
Pharmacotherapy of Psoriasis |
|
|
1378 | (5) |
|
|
|
1381 | (1) |
|
|
|
1381 | (2) |
|
Pharmacotherapy of Minor Skin Burns |
|
|
1383 | (2) |
|
Prototype Drug: Benzocaine (Americaine, Anbesol, Others) |
|
|
1384 | (1) |
|
Pharmacotherapy of Alopecia |
|
|
1385 | (4) |
|
74 Pharmacotherapy of Eye and Ear Disorders |
|
|
1389 | (20) |
|
|
|
1390 | (2) |
|
Pathophysiology of Glaucoma |
|
|
1392 | (1) |
|
Pharmacotherapy of Glaucoma |
|
|
1393 | (6) |
|
Prototype Drug: Latanoprost (Xalatan) |
|
|
1393 | (3) |
|
Prototype Drug: Timolol (Betimol, Timoptic, Others) |
|
|
1396 | (2) |
|
Miscellaneous Drugs for Treating Glaucoma |
|
|
1398 | (1) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Glaucoma |
|
|
1398 | (1) |
|
Pharmacotherapy for Eye Examinations |
|
|
1399 | (2) |
|
Pharmacotherapy for Other Eye Conditions |
|
|
1401 | (1) |
|
|
|
1402 | (1) |
|
Pharmacotherapy with Otic Preparations |
|
|
1402 | (7) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Otitis |
|
|
1405 | (4) |
|
75 Emergency Preparedness: Bioterrorism and Management of Poisoning |
|
|
1409 | (16) |
|
Emergency Preparedness, Bioterrorism, and Nursing |
|
|
1410 | (2) |
|
|
|
1412 | (2) |
|
Chemical and Physical Agents |
|
|
1414 | (2) |
|
|
|
1416 | |
|
Prototype Drug: Activated Charcoal (CharcoAid) |
|
|
1418 | (1) |
|
Prototype Drug: Edetate Calcium Disodium (Calcium EDTA) |
|
|
1419 | (1) |
|
Prototype Drug: Dimercaprol (BAL in Oil) |
|
|
1419 | (1) |
|
Connections: Nursing Practice Application Patients Receiving Pharmacotherapy for Poisoning or Overdose |
|
|
1420 | |
| Appendices |
|
|
A Answers to
Chapter Review |
|
|
1425 | (32) |
|
B ISMP List of High-Alert Medications in Acute Care Settings |
|
|
1457 | (1) |
| Glossary |
|
1458 | (19) |
| Credits |
|
1477 | (1) |
| Index |
|
1478 | |
